Cambrex Expands Large-Scale Manufacturing Capacity at Iowa Site
The API manufacturer has announced that it has completed the expansion of large-scale manufacturing capabilities at its Charles City, Iowa site.
On Oct. 23, 2017, Cambrex, a manufacturer of APIs, announced the completion of a large-scale manufacturing expansion of the company's Charles City, Iowa facility. The investment included the installation of 1000- and 4000-gallon glass-lined reactors, in addition to ancillary equipment.
The reactors have been installed in the 7500-ft2 manufacturing facility, which opened at the site in 2016. With the new reactors, cGMP reactor capacity has reached 23,000 gallons, with the total capacity at the Charles City facility now approximately 107,000 gallons. According to Shawn Cavanagh, COO of Cambrex, the newly-expanded plant will facilitate projects transferred from other company sites.
The Charles City facility is located on a 45-acre site and manufactures a range of APIs and pharmaceutical intermediates, including highly potent molecules and controlled substances. Additionally, the facility is authorized by the United States Drug Enforcement Administration to import narcotic raw materials at commercial scale, according to the company.
This investment comes after the installation of a new pilot plant at the site in 2017 and recent announcements of expansions across other manufacturing sites, including the construction of a $24-million, 4500ft2 highly potent API manufacturing facility at its Charles City, Iowa site, which is due to open in 2019.
Source: Cambrex
VERAXA and Voyager to Create Combined Business for Advancing Pipeline of Next-Gen Cancer Therapies
April 23rd 2025The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company that will focus on developing a pipeline of next-generation cancer therapies.
Tokyo University of Science Research Team Explores Improved Delivery of Antisense Oligonucleotides
April 18th 2025Using cholesterol-modified oligonucleotides, the research team aims to improve the delivery of antisense nucleotide-based therapies for treating neurodegenerative diseases and brain cancers.
